{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:43:23Z","timestamp":1792597403369,"version":"4.5.0"},"reference-count":275,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R15AI047115"],"award-info":[{"award-number":["2R15AI047115"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Aminoglycosides are a group of antibiotics used since the 1940s to primarily treat a broad spectrum of bacterial infections. The primary resistance mechanism against these antibiotics is enzymatic modification by aminoglycoside-modifying enzymes that are divided into acetyl-transferases, phosphotransferases, and nucleotidyltransferases. To overcome this problem, new semisynthetic aminoglycosides were developed in the 70s. The most widely used semisynthetic aminoglycoside is amikacin, which is refractory to most aminoglycoside modifying enzymes. Amikacin was synthesized by acylation with the l-(\u2212)-\u03b3-amino-\u03b1-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A. The main amikacin resistance mechanism found in the clinics is acetylation by the aminoglycoside 6\u2032-N-acetyltransferase type Ib [AAC(6\u2032)-Ib], an enzyme coded for by a gene found in integrons, transposons, plasmids, and chromosomes of Gram-negative bacteria. Numerous efforts are focused on finding strategies to neutralize the action of AAC(6\u2032)-Ib and extend the useful life of amikacin. Small molecules as well as complexes ionophore-Zn+2 or Cu+2 were found to inhibit the acetylation reaction and induced phenotypic conversion to susceptibility in bacteria harboring the aac(6\u2032)-Ib gene. A new semisynthetic aminoglycoside, plazomicin, is in advance stage of development and will contribute to renewed interest in this kind of antibiotics.<\/jats:p>","DOI":"10.3390\/molecules22122267","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T10:48:40Z","timestamp":1513680520000},"page":"2267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":248,"title":["Amikacin: Uses, Resistance, and Prospects for Inhibition"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-7890","authenticated-orcid":false,"given":"Maria","family":"Ramirez","sequence":"first","affiliation":[{"name":"Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-7811","authenticated-orcid":false,"given":"Marcelo","family":"Tolmasky","sequence":"additional","affiliation":[{"name":"Center for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, Fullerton, CA 92831, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.16.3.430-450.2003","article-title":"Versatility of aminoglycosides and prospects for their future","volume":"16","author":"Vakulenko","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1128\/AAC.44.12.3249-3256.2000","article-title":"Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance","volume":"44","author":"Kotra","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/cbic.200900779","article-title":"The future of aminoglycosides: The end or renaissance?","volume":"11","author":"Houghton","year":"2010","journal-title":"ChemBioChem"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mayers, D., Sobel, J., Ouellette, M., Kaye, K., and Marchaim, D. (2017). Aminoglycosides: Mechanisms of action and resistance. Antimicrobial Drug Resistance, Springer.","DOI":"10.1007\/978-3-319-46718-4"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pullens, B., and van Benthem, P.P. (2011). Intratympanic gentamicin for Meniere\u2019s disease or syndrome. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD008234.pub2"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exer.2017.01.001","article-title":"Mechanism and evidence of nonsense suppression therapy for genetic eye disorders","volume":"155","author":"Richardson","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/10409238.2012.694846","article-title":"Suppression of premature termination codons as a therapeutic approach","volume":"47","author":"Keeling","year":"2012","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2005-03-1307","article-title":"Aminoglycoside suppression of nonsense mutations in severe hemophilia","volume":"106","author":"James","year":"2005","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/emboj\/19.1.1","article-title":"Modulation of RNA function by aminoglycoside antibiotics","volume":"19","author":"Schroeder","year":"2000","journal-title":"EMBO J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bryskier, A. (2005). Aminocyclitol aminoglycosides. Antimicrobial Agents, ASM Press.","DOI":"10.1128\/9781555815929"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ja.2006.73","article-title":"Aminoglycosides: Ancient and modern","volume":"59","author":"Davies","year":"2006","journal-title":"J. Antibiot."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.100.2588.103.b","article-title":"Control of gram-negative bacteria in experimental animals by streptomycin","volume":"100","author":"Jones","year":"1944","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.109.2830.305","article-title":"Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms","volume":"109","author":"Waksman","year":"1949","journal-title":"Science"},{"key":"ref_14","first-page":"232","article-title":"Studies on streptothricin group substances. On streptothricin A and streptothricin B","volume":"3","author":"Umezawa","year":"1949","journal-title":"J. Antibiot."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1749-6632.1958.tb54688.x","article-title":"Kanamycin: Its discovery","volume":"76","author":"Umezawa","year":"1958","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_16","first-page":"1","article-title":"Gentamicin, a new broad-spectrum antibiotic complex","volume":"161","author":"Weinstein","year":"1963","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/jm00340a034","article-title":"Gentamicin, a new antibiotic complex from Micromonospora","volume":"6","author":"Weinstein","year":"1963","journal-title":"J. Med. Chem."},{"key":"ref_18","first-page":"324","article-title":"Nebramycin, a new broad-spectrum antibiotic complex. II. Description of Streptomyces tenebrarius","volume":"7","author":"Higgins","year":"1967","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1039\/C5MD00453E","article-title":"A review of patents (2011\u20132015) towards combating resistance to and toxicity of aminoglycosides","volume":"7","author":"Chandrika","year":"2016","journal-title":"MedChemComm"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1021\/acs.joc.5b00248","article-title":"Structure-activity relationships for antibacterial to antifungal conversion of kanamycin to amphiphilic analogues","volume":"80","author":"Fosso","year":"2015","journal-title":"J. Org. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1128\/AAC.00229-15","article-title":"Amphiphilic tobramycin analogues as antibacterial and antifungal agents","volume":"59","author":"Shrestha","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bonomo, R.A., and Tolmasky, M.E. (2007). Aminoglycoside-modifying enzymes: Characteristics, localization, and dissemination. Enzyme-Mediated Resistance to Antibiotics: Mechanisms, Dissemination, and Prospects for Inhibition, ASM Press.","DOI":"10.1128\/9781555815615"},{"key":"ref_24","first-page":"1077","article-title":"Antibacterial agents","volume":"Volume 1","author":"Murray","year":"2007","journal-title":"Manual of Clinical Microbiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1039\/C2NP20092A","article-title":"2-Deoxystreptamine-containing aminoglycoside antibiotics: Recent advances in the characterization and manipulation of their biosynthetic pathways","volume":"30","author":"Park","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Updat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/mr.57.1.138-163.1993","article-title":"Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes","volume":"57","author":"Shaw","year":"1993","journal-title":"Microbiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-68579-8_6","article-title":"Mechanisms of resistance to amino-glycoside antibiotics","volume":"Volume 62","author":"Umezawa","year":"1982","journal-title":"Aminoglycoside Antibiotics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1039\/C5MD00344J","article-title":"Mechanisms of resistance to aminoglycoside antibiotics: Overview and perspectives","volume":"7","author":"Labby","year":"2016","journal-title":"MedChemComm"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fmicb.2015.00034","article-title":"Mechanisms of antibiotic resistance","volume":"6","author":"Lin","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_31","first-page":"136","article-title":"Isolation and structure of kanamycin inactivated by a cell free system of kanamycin-resistant E. coli","volume":"20","author":"Umezawa","year":"1967","journal-title":"J. Antibiot."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.biochem.5b01269","article-title":"Bacterial GCN5-related N-acetyltransferases: From resistance to regulation","volume":"55","author":"Favrot","year":"2016","journal-title":"Biochemistry"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Salah Ud-Din, A.I., Tikhomirova, A., and Roujeinikova, A. (2016). Structure and functional diversity of GCN5-related N-acetyltransferases (GNAT). Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071018"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fmicb.2013.00121","article-title":"Rise and dissemination of aminoglycoside resistance: The aac(6\u2032)-Ib paradigm","volume":"4","author":"Ramirez","year":"2013","journal-title":"Front. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s101560050001","article-title":"Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications","volume":"5","author":"Kondo","year":"1999","journal-title":"J. Infect. Chemother."},{"key":"ref_36","first-page":"47","article-title":"Action mechanism of 3\u2032,4\u2032-dideoxykanamycin B (DKB) on Klebsiella pneumoniae","volume":"21","author":"Oizumi","year":"1974","journal-title":"Sci. Rep. Res. Inst. Tohoku Univ. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7164\/antibiotics.24.485","article-title":"3\u2032,4\u2032-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa","volume":"24","author":"Umezawa","year":"1971","journal-title":"J. Antibiot."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7164\/antibiotics.25.695","article-title":"BB-K8, a new semisynthetic aminoglycoside antibiotic","volume":"25","author":"Kawaguchi","year":"1972","journal-title":"J. Antibiot."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/AAC.32.9.1416","article-title":"Transposon-mediated amikacin resistance in Klebsiella pneumoniae","volume":"32","author":"Tolmasky","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.31.12.1955","article-title":"Tn1331, a novel multiresistance transposon encoding resistance to amikacin and ampicillin in Klebsiella pneumoniae","volume":"31","author":"Tolmasky","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/AAC.30.2.315","article-title":"Molecular cloning of amikacin resistance determinants from a Klebsiella pneumoniae plasmid","volume":"30","author":"Tolmasky","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/AAC.29.2.315","article-title":"Plasmid-encoded amikacin resistance in multiresistant strains of Klebsiella pneumoniae isolated from neonates with meningitis","volume":"29","author":"Woloj","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"D20","DOI":"10.2741\/A493","article-title":"Bacterial resistance to aminoglycosides and \u03b2-lactams: The Tn1331 transposon paradigm","volume":"5","author":"Tolmasky","year":"2000","journal-title":"Front. Biosci."},{"key":"ref_44","unstructured":"Mangia, A., Giobbio, V., and Ornato, G. (1990). Novel Process for the Synthesis of Amikacin. (4,902,790), U.S. Patent."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0040-4039(01)85445-9","article-title":"Aminoglycoside antibiotics\u2014A method for selective N-acylation based on the temporary protection of amino alcohol functions as copper chelates","volume":"19","author":"Hanessian","year":"1978","journal-title":"Tetrahedron Lett."},{"key":"ref_46","first-page":"74","article-title":"Netilmicin: Clinical pharmacokinetics and aspects on dosage schedules. An overview","volume":"12","author":"Kahlmeter","year":"1980","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7164\/antibiotics.31.681","article-title":"The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B","volume":"31","author":"Nagabhushan","year":"1978","journal-title":"J. Antibiot."},{"key":"ref_48","first-page":"561","article-title":"Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus","volume":"47","author":"Kondo","year":"1994","journal-title":"Jpn. J. Antibiot."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4155\/fmc.13.80","article-title":"Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections","volume":"5","author":"Labby","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.copbio.2017.03.019","article-title":"Biosynthetic pathways of aminoglycosides and their engineering","volume":"48","author":"Park","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/acsmedchemlett.5b00255","article-title":"Synthesis and biological activity of mono- and di-N-acylated aminoglycosides","volume":"6","author":"Chandrika","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/QCO.0000000000000012","article-title":"Aminoglycosides: How should we use them in the 21st century?","volume":"26","author":"Jackson","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/13543776.2010.506189","article-title":"New aminoglycoside antibiotics","volume":"20","author":"Dozzo","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1039\/c2md00253a","article-title":"Understanding and overcoming aminoglycoside resistance caused by N-6\u2032-acetyltransferase","volume":"3","author":"Vong","year":"2012","journal-title":"MedChemComm"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.2174\/156802610793176684","article-title":"Development of aminoglycoside antibiotics effective against resistant bacterial strains","volume":"10","author":"Yang","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.1021\/acs.jmedchem.6b00818","article-title":"New broad-spectrum antibacterial amphiphilic aminoglycosides active against resistant bacteria: From neamine derivatives to smaller neosamine analogues","volume":"59","author":"Zimmermann","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/cmdc.201402175","article-title":"Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria","volume":"9","author":"Fair","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1128\/AAC.00223-09","article-title":"In Vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic","volume":"53","author":"You","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","article-title":"Combating evolution with intelligent design: The neoglycoside ACHN-490","volume":"13","author":"Armstrong","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ijantimicag.2015.07.021","article-title":"In Vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains","volume":"46","author":"Pena","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_63","unstructured":"Arrington, D. (2017, November 02). Achaogen submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections. Available online: http:\/\/investors.achaogen.com\/releasedetail.cfm?releaseid=1045559."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/jac\/dkx239","article-title":"Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates","volume":"72","author":"Poirel","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/jac\/dkx261","article-title":"In Vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE)","volume":"72","author":"Zhang","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1128\/AAC.00873-15","article-title":"Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?","volume":"59","author":"Picazo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In Vitro activity of plazomicin against 5015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011\u20132012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijantimicag.2017.01.039","article-title":"In-Vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: Potency of plazomicin alone and in combination with other agents","volume":"50","author":"Rios","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_70","unstructured":"(2017). British National Formulary, The Royal Pharmaceutical Society of Great Britain."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/35.1.167","article-title":"The role of lipopolysaccharide anionic binding sites in aminoglycoside uptake in Stenotrophomonas (Xanthomonas) maltophilia","volume":"35","author":"Vanhoof","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","first-page":"2015","article-title":"Effect of growth rate on streptomycin accumulation by Escherichia coli and Bacillus megaterium","volume":"130","author":"Muir","year":"1984","journal-title":"J. Gen. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj2280505","article-title":"Respiration-dependent uptake of dihydrostreptomycin by Escherichia coli. Its irreversible nature and lack of evidence for a uniport process","volume":"228","author":"Nichols","year":"1985","journal-title":"Biochem. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.12.2.163","article-title":"Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: A model for entry of streptomycin and gentamicin in susceptible and resistant bacteria","volume":"12","author":"Bryan","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0005-2787(81)90220-3","article-title":"Role of ribosome recycling in uptake of dihydrostreptomycin by sensitive and resistant Escherichia coli","volume":"652","author":"Hurwitz","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/24.1.77","article-title":"Non-specific membrane permeability and aminoglycoside action","volume":"24","author":"Davis","year":"1989","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jac\/23.5.673","article-title":"The enigma of streptomycin transport","volume":"23","author":"Nichols","year":"1989","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.32.4.518","article-title":"Inhibition of tobramycin diffusion by binding to alginate","volume":"32","author":"Nichols","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/mr.51.4.439-457.1987","article-title":"Bacterial uptake of aminoglycoside antibiotics","volume":"51","author":"Taber","year":"1987","journal-title":"Microbiol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1099\/00221287-138-3-563","article-title":"Aminoglycoside and aminocyclitol antibiotics: Hygromycin B is an atypical bactericidal compound that exerts effects on cells of Escherichia coli characteristics for bacteriostatic aminocyclitols","volume":"138","author":"Bakker","year":"1992","journal-title":"J. Gen. Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/00221287-138-3-551","article-title":"The bactericidal action of streptomycin: Membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells due to degradation of these proteins","volume":"138","author":"Busse","year":"1992","journal-title":"J. Gen. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/mr.51.3.341-350.1987","article-title":"Mechanism of bactericidal action of aminoglycosides","volume":"51","author":"Davis","year":"1987","journal-title":"Microbiol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/cr0301088","article-title":"Molecular insights into aminoglycoside action and resistance","volume":"105","author":"Magnet","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acsinfecdis.6b00176","article-title":"Antimicrobial activity, AME resistance, and A-site binding studies of anthraquinone-neomycin conjugates","volume":"3","author":"Degtyareva","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1389450053765860","article-title":"Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance","volume":"6","author":"Jana","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00253-005-0279-0","article-title":"Molecular understanding of aminoglycoside action and resistance","volume":"70","author":"Jana","year":"2006","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/wrna.60","article-title":"Antibiotics that target protein synthesis","volume":"2","author":"McCoy","year":"2011","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00203-007-0334-6","article-title":"Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin","volume":"189","author":"Foster","year":"2008","journal-title":"Arch. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00284-002-3945-9","article-title":"Neomycin and paromomycin inhibit 30S ribosomal subunit assembly in Staphylococcus aureus","volume":"47","author":"Mehta","year":"2003","journal-title":"Curr. Microbiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1039\/B813252F","article-title":"Cleavage of RNA oligonucleotides by aminoglycosides","volume":"7","author":"Belousoff","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/iub.105","article-title":"Insights into functional modulation of catalytic RNA activity","volume":"60","author":"Vourekas","year":"2008","journal-title":"IUBMB Life"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.bbrc.2006.04.037","article-title":"Mg2+ mimicry in the promotion of group I ribozyme activities by aminoglycoside antibiotics","volume":"344","author":"Bao","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1073\/pnas.96.11.6155","article-title":"Inhibition of RNase P RNA cleavage by aminoglycosides","volume":"96","author":"Mikkelsen","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/nar\/gkm1088","article-title":"Studies on the mechanism of inhibition of bacterial ribonuclease P by aminoglycoside derivatives","volume":"36","author":"Kawamoto","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17025","DOI":"10.1073\/pnas.252607699","article-title":"Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics","volume":"99","author":"Goh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1128\/AAC.00892-06","article-title":"Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics","volume":"51","author":"Possoz","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0885066610377968","article-title":"Management of aminoglycosides in the intensive care unit","volume":"25","author":"Radigan","year":"2010","journal-title":"J. Intensive Care Med."},{"key":"ref_98","first-page":"45","article-title":"Neuromuscular blocking activity of aminoglycoside antibiotics","volume":"2","author":"Paradelis","year":"1980","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bja\/50.2.109","article-title":"Some effects of the aminoglycoside antibiotic amikacin on neuromuscular and autonomic transmission","volume":"50","author":"Singh","year":"1978","journal-title":"Br. J. Anaesth."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1503\/cmaj.140339","article-title":"Aminoglycoside-induced ototoxicity","volume":"187","author":"Leis","year":"2015","journal-title":"CMAJ"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thx.2009.131532","article-title":"Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis","volume":"65","author":"Prayle","year":"2010","journal-title":"Thorax"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/00016480050218627","article-title":"Vestibular and cochlear toxicity of aminoglycosides\u2014A review","volume":"120","author":"Nakashima","year":"2000","journal-title":"Acta Otolaryngol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: Mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Parfitt","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tox.2008.04.015","article-title":"Aminoglycoside induced ototoxicity","volume":"249","author":"Guthrie","year":"2008","journal-title":"Toxicology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMc053428","article-title":"Aspirin to prevent gentamicin-induced hearing loss","volume":"354","author":"Sha","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.ki.5002295","article-title":"Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine","volume":"72","author":"Feldman","year":"2007","journal-title":"Kidney Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fncel.2017.00262","article-title":"d-Tubocurarine and berbamine: Alkaloids that are permeant blockers of the hair cell\u2019s mechano-electrical transducer channel and protect from aminoglycoside toxicity","volume":"11","author":"Kirkwood","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: Nephrotoxicity","volume":"43","author":"Tulkens","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00467-016-3533-z","article-title":"Aminoglycoside-induced nephrotoxicity in children","volume":"32","author":"McWilliam","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tox.2016.12.003","article-title":"A systematic meta-analysis on the efficacy of pre-clinically tested nephroprotectants at preventing aminoglycoside nephrotoxicity","volume":"377","author":"Casanova","year":"2017","journal-title":"Toxicology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1128\/AAC.35.7.1284","article-title":"Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital","volume":"35","author":"Gerding","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Gad, G.F., Mohamed, H.A., and Ashour, H.M. (2011). Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017224"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","article-title":"Amikacin in critically ill patients: A review of population pharmacokinetic studies","volume":"56","author":"Marsot","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_115","first-page":"4407","article-title":"Clinical pharmacokinetics of amikacin in neonates","volume":"5","author":"Pacifici","year":"2017","journal-title":"Int. J. Pediatr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.1977.03280100027017","article-title":"Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms","volume":"238","author":"Yu","year":"1977","journal-title":"JAMA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archinte.1978.03630290029013","article-title":"Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli","volume":"138","author":"Sklaver","year":"1978","journal-title":"Arch. Intern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00007691-198503000-00003","article-title":"An overview of amikacin","volume":"7","author":"Ristuccia","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s15010-009-9193-9","article-title":"Nocardiosis: Updated clinical review and experience at a tertiary center","volume":"38","author":"Ambrosioni","year":"2010","journal-title":"Infection"},{"key":"ref_121","first-page":"93","article-title":"Mycobacterial endocarditis: A comprehensive review","volume":"30","author":"Yuan","year":"2015","journal-title":"Rev. Bras. Cir. Cardiovasc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1128\/AAC.01032-15","article-title":"Optimizing the initial amikacin dosage in adults","volume":"59","author":"White","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","unstructured":"Brunton, L., Chamber, B., and Knollman, B. (2011). Aminogylcosides. The Pharmacological Basis of Therapeutics, Mc Graw Hill."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-009-0637-4","article-title":"Individualised dosing of amikacin in neonates: A pharmacokinetic\/pharmacodynamic analysis","volume":"65","author":"Sherwin","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_126","first-page":"486","article-title":"Therapeutic drug monitoring of amikacin in preterm and term infants","volume":"50","author":"Siddiqi","year":"2009","journal-title":"Singap. Med. J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1128\/AAC.00277-11","article-title":"Quantification of amikacin in bronchial epithelial lining fluid in neonates","volume":"55","author":"Tayman","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.biochi.2006.05.017","article-title":"Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the \u03b3-amino-\u03b1-hydroxybutyryl (haba) group","volume":"88","author":"Kondo","year":"2006","journal-title":"Biochimie"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1021\/ja029736h","article-title":"The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography","volume":"125","author":"Russell","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e01763-16","DOI":"10.1128\/AAC.01763-16","article-title":"Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: Experimental basis for combination therapy","volume":"61","author":"Sime","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Hassan, N.A., Awdallah, F.F., Abbassi, M.M., and Sabry, N.A. (2017). Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: A randomized controlled trial. Crit. Care Med.","DOI":"10.1097\/CCM.0000000000002695"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yagi, K., Ishii, M., Namkoong, H., Asami, T., Iketani, O., Asakura, T., Suzuki, S., Sugiura, H., Yamada, Y., and Nishimura, T. (2017). The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2665-5"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10096-008-0620-5","article-title":"Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: Safety and feasibility in the era of escalating drug resistance","volume":"28","author":"Ghannam","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Davis, K.K., Kao, P.N., Jacobs, S.S., and Ruoss, S.J. (2007). Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: An observational case series. BMC Pulm. Med., 7.","DOI":"10.1186\/1471-2466-7-2"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2017.01.002","article-title":"Intrathecal or intraventricular administration of colistin, vancomycin and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit","volume":"49","author":"Tsimogianni","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/318698","article-title":"Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: Case report","volume":"32","author":"Berning","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"818","DOI":"10.5588\/ijtld.16.0791","article-title":"Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease","volume":"21","author":"Lee","year":"2017","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Sima, M., Hartinger, J., Cikankova, T., and Slanar, O. (2017). Estimation of once-daily amikacin dose in critically ill adults. J. Chemother., 1\u20137.","DOI":"10.1080\/1120009X.2017.1376818"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/27.suppl_C.49","article-title":"Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin","volume":"27","author":"Tulkens","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: Do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s002280100355","article-title":"Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation","volume":"57","author":"Bleyzac","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000047133","article-title":"Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models","volume":"80","author":"Labaune","year":"2001","journal-title":"Biol. Neonate"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/AAC.10.2.205","article-title":"Amikacin in newborn infants: Comparative pharmacology with kanamycin and clinical efficacy in 45 neonates with bacterial diseases","volume":"10","author":"Howard","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_148","first-page":"348","article-title":"Neonatal sepsis: High antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit in Karachi","volume":"52","author":"Mahmood","year":"2002","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_149","first-page":"33","article-title":"Comparison of amikacin pharmacokinetics in neonates following implementation of a new dosage protocol","volume":"22","author":"Hughes","year":"2017","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.36.8.1596","article-title":"Increased resistance to amikacin in a neonatal unit following intensive amikacin usage","volume":"36","author":"Friedland","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/48.3.333","article-title":"Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies","volume":"48","author":"Schiffelers","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_152","first-page":"136","article-title":"Urinary tract infection treatment using liposomal amikacin (MiKasome)","volume":"Volume 5S3","author":"Krieger","year":"1999","journal-title":"Proceedings of the Ninth European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1128\/AAC.43.7.1737","article-title":"Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: Microbiological and echocardiographic analyses","volume":"43","author":"Xiong","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1128\/AAC.32.9.1404","article-title":"Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice","volume":"32","author":"Duzgunes","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1128\/AAC.45.2.464-470.2001","article-title":"Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin","volume":"45","author":"Schiffelers","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/infdis\/135.Supplement_2.S249","article-title":"Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates","volume":"134","author":"Price","year":"1976","journal-title":"J. Infect. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.5.2.143","article-title":"Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics","volume":"5","author":"Price","year":"1974","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/clinids\/24.Supplement_1.S46","article-title":"The most frequent aminoglycoside resistance mechanisms\u2014Changes with time and geographic area: A reflection of aminoglycoside usage patterns?","volume":"24","author":"Miller","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/AAC.6.6.807","article-title":"Properties of an R plasmid in Pseudomonas aeruginosa producing amikacin (BB-K8), butirosin, kanamycin, tobramycin, and sisomicin resistance","volume":"6","author":"Jacoby","year":"1974","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/br.40.1.168-189.1976","article-title":"Uniform nomenclature for bacterial plasmids: A proposal","volume":"40","author":"Novick","year":"1976","journal-title":"Bacteriol. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1128\/AAC.7.5.494","article-title":"R factor-mediated aminoglycoside antibiotic resistance in Pseudomonas aeruginosa: A new aminoglycoside 6\u2032-N-acetyltransferase","volume":"7","author":"Kawabe","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/AAC.7.1.50","article-title":"Acetylation of amikacin, a new semisynthetic antibiotic, by Pseudomonas aeruginosa carrying an R factor","volume":"7","author":"Kawabe","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1099\/00221287-94-2-389","article-title":"Isolation and characterization of mutants of Escherichia coli K12 resistant to the new aminoglycoside antibiotic, amikacin","volume":"94","author":"Hull","year":"1976","journal-title":"J. Gen. Microbiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.16.5.598","article-title":"Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli","volume":"16","author":"Perlin","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.29.2.216","article-title":"High-level amikacin resistance in Escherichia coli due to phosphorylation and impaired aminoglycoside uptake","volume":"29","author":"Perlin","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/AAC.20.3.344","article-title":"Aminoglycoside phosphotransferase-II-mediated amikacin resistance in Escherichia coli","volume":"20","author":"Bongaerts","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/AAC.20.1.75","article-title":"New plasmid-mediated aminoglycoside adenylyltransferase of broad substrate range that adenylylates amikacin","volume":"20","author":"Coombe","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7326\/0003-4819-96-2-176","article-title":"In-vivo acquisition of two different types of aminoglycoside resistance by a single strain of Klebsiella pneumoniae causing severe infection","volume":"96","author":"Murray","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1542\/peds.65.2.264","article-title":"Outbreak of amikacin-resistant Enterobacteriaceae in an intensive care nursery","volume":"65","author":"Cook","year":"1980","journal-title":"Pediatrics"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1086\/515328","article-title":"A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae","volume":"177","author":"Prammananan","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1128\/AAC.00851-09","article-title":"High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene","volume":"53","author":"Jugheli","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/mdr.2011.0063","article-title":"Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis","volume":"18","author":"Sirgel","year":"2012","journal-title":"Microb. Drug Resist."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diagmicrobio.2013.06.031","article-title":"Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China","volume":"77","author":"Du","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijmyco.2015.09.001","article-title":"Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables","volume":"5","author":"Kambli","year":"2016","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Tsodikov, O.V., Green, K.D., and Garneau-Tsodikova, S. (2014). A random sequential mechanism of aminoglycoside acetylation by Mycobacterium tuberculosis Eis protein. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092370"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1073\/pnas.1105379108","article-title":"Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB","volume":"108","author":"Chen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.47.2.697-703.2003","article-title":"Salmonella enterica serovar Typhimurium bla(PER-1)-carrying plasmid pSTI1 encodes an extended-spectrum aminoglycoside 6\u2032-N-acetyltransferase of type Ib","volume":"47","author":"Casin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nm1347","article-title":"Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase","volume":"12","author":"Robicsek","year":"2006","journal-title":"Nat. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.mib.2009.06.013","article-title":"The bifunctional enzymes of antibiotic resistance","volume":"12","author":"Zhang","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1128\/AAC.46.5.1402-1409.2002","article-title":"Presence of a group II intron in a multiresistant Serratia marcescens strain that harbors three integrons and a novel gene fusion","volume":"46","author":"Centron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1021\/bi049135y","article-title":"Domain-domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6\u2032)-APH(2\u2033)","volume":"43","author":"Boehr","year":"2004","journal-title":"Biochemistry"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/jb.167.2.631-638.1986","article-title":"Nucleotide sequence analysis of the gene specifying the bifunctional 6\u2032-aminoglycoside acetyltransferase 2\u2033-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities","volume":"167","author":"Ferretti","year":"1986","journal-title":"J. Bacteriol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.2741\/culebras","article-title":"Aminoglycoside resistance mediated by the bifunctional enzyme 6\u2032-N-aminoglycoside acetyltransferase-2\u2033-O-aminoglycoside phosphotransferase","volume":"4","author":"Culebras","year":"1999","journal-title":"Front. Biosci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/AAC.46.3.638-645.2002","article-title":"Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac(3)-Ib\/aac(6\u2033)-Ib\u2033 gene cassettes in Pseudomonas aeruginosa","volume":"46","author":"Dubois","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1128\/AAC.48.12.4693-4702.2004","article-title":"Integron carrying a novel metallo-\u03b2-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistance gene aac(6\u2032)-30\/aac(6\u2032)-Ib\u2032: Report from the SENTRY antimicrobial surveillance program","volume":"48","author":"Mendes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1128\/AAC.01400-07","article-title":"In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6\u2032-APH2\u2033 enzyme","volume":"52","author":"Li","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.37.9.1896","article-title":"Characterization of the chromosomal aac(6\u2032)-Ii gene specific for Enterococcus faecium","volume":"37","author":"Costa","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/AAC.45.10.2691-2694.2001","article-title":"Aminoglycoside resistance genes aph(2\u2033)-Ib and aac(6\u2032)-Im detected together in strains of both Escherichia coli and Enterococcus faecium","volume":"45","author":"Chow","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_190","first-page":"3039","article-title":"The aacA-aphD gentamicin and kanamycin resistance determinant of Tn4001 from Staphylococcus aureus: Expression and nucleotide sequence analysis","volume":"133","author":"Rouch","year":"1987","journal-title":"J. Gen. Microbiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dki347","article-title":"Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy","volume":"56","author":"Zarrilli","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1021\/acs.biochem.6b00770","article-title":"Expanding aminoglycoside resistance enzyme regiospecificity by mutation and truncation","volume":"55","author":"Holbrook","year":"2016","journal-title":"Biochemistry"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10096-013-1868-y","article-title":"High abundance and diversity of antimicrobial resistance determinants among early vancomycin-resistant Enterococcus faecium in Poland","volume":"32","author":"Sadowy","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/AAC.00603-06","article-title":"High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus","volume":"51","author":"Chow","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/00222615-23-2-101","article-title":"Plasmid-mediated resistance to gentamicin in Staphylococcus aureus: The involvement of a transposon","volume":"23","author":"Lyon","year":"1987","journal-title":"J. Med. Microbiol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/00222615-24-2-139","article-title":"Chromosome- and plasmid-mediated gentamicin resistance in Staphylococcus aureus encoded by Tn4001","volume":"24","author":"Gillespie","year":"1987","journal-title":"J. Med. Microbiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/AAC.35.6.1147","article-title":"Characterization of the gentamicin resistance transposon Tn5281 from Enterococcus faecalis and comparison to staphylococcal transposons Tn4001 and Tn4031","volume":"35","author":"Murray","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1128\/AAC.33.8.1335","article-title":"Mobility of gentamicin resistance genes from staphylococci isolated in the United States: Identification of Tn4031, a gentamicin resistance transposon from Staphylococcus epidermidis","volume":"33","author":"Thomas","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.str.2016.04.002","article-title":"Antibiotic binding drives catalytic activation of aminoglycoside kinase APH(2\u2033)-Ia","volume":"24","author":"Caldwell","year":"2016","journal-title":"Structure"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1107\/S1399004714005331","article-title":"Structure of the phosphotransferase domain of the bifunctional aminoglycoside-resistance enzyme AAC(6\u2032)-Ie-APH(2\u2033)-Ia","volume":"70","author":"Smith","year":"2014","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1107\/S1399004714017635","article-title":"Structure of the bifunctional aminoglycoside-resistance enzyme AAC(6\u2032)-Ie-APH(2\u2033)-Ia revealed by crystallographic and small-angle X-ray scattering analysis","volume":"70","author":"Smith","year":"2014","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1110\/ps.0233503","article-title":"X-ray structure of the AAC(6\u2032)-Ii antibiotic resistance enzyme at 1.8 A resolution; examination of oligomeric arrangements in GNAT superfamily members","volume":"12","author":"Burk","year":"2003","journal-title":"Protein Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1107\/S0907444905021487","article-title":"Structures of aminoglycoside acetyltransferase AAC(6\u2032)-Ii in a novel crystal form: Structural and normal-mode analyses","volume":"61","author":"Burk","year":"2005","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1021\/bi034148h","article-title":"Kinetic mechanism of the GCN5-related chromosomal aminoglycoside acetyltransferase AAC(6\u2032)-Ii from Enterococcus faecium: Evidence of dimer subunit cooperativity","volume":"42","author":"Draker","year":"2003","journal-title":"Biochemistry"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.49.7.2979-2982.2005","article-title":"Mutagenesis analysis of a conserved region involved in acetyl coenzyme A binding in the aminoglycoside 6\u2032-N-acetyltransferase type Ib encoded by plasmid pJHCMW1","volume":"49","author":"Pourreza","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1128\/AAC.00493-08","article-title":"The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae","volume":"52","author":"Rice","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.PLAS-0016-2013","article-title":"Plasmid-mediated antibiotic resistance and virulence in Gram-negatives: The Klebsiella pneumoniae paradigm","volume":"2","author":"Ramirez","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/jac\/dkr548","article-title":"qnr, aac(6\u2032)-Ib-cr and qepA genes in Escherichia coli and Klebsiella spp.: Genetic environments and plasmid and chromosomal location","volume":"67","author":"Ruiz","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_210","first-page":"e00212","article-title":"Draft genome of the multidrug-resistant Acinetobacter baumannii strain A155 clinical isolate","volume":"3","author":"Arivett","year":"2015","journal-title":"Genome Announc."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1128\/AAC.00398-06","article-title":"Class II transposon-borne structure harboring metallo-\u03b2-lactamase gene blaVIM-2 in Pseudomonas putida","volume":"50","author":"Poirel","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_212","first-page":"543","article-title":"Dissemination of plasmid-mediated amikacin resistance among pathogenic Klebsiella pneumoniae","volume":"50","author":"Chamorro","year":"1990","journal-title":"Medicina"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1128\/AAC.00688-09","article-title":"Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone","volume":"53","author":"Woodford","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1128\/AAC.01397-13","article-title":"Complete nucleotide sequence of a blaKPC-harboring IncI2 plasmid and its dissemination in New Jersey and New York hospitals","volume":"57","author":"Chen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mib.2017.03.002","article-title":"Class 1 integrons as invasive species","volume":"38","author":"Gillings","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Escudero, J.A., Loot, C., Nivina, A., and Mazel, D. (2015). The integron: Adaptation on demand. Microbiol. Spectr., 3.","DOI":"10.1128\/microbiolspec.MDNA3-0019-2014"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkn279","article-title":"Functional characterization of Tn1331 gene cassettes","volume":"62","author":"Ramirez","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1128\/AAC.01313-08","article-title":"A blaVEB-1 variant, blaVEB-6, associated with repeated elements in a complex genetic structure","volume":"53","author":"Zong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1128\/jb.169.12.5708-5714.1987","article-title":"Primary structure of an aminoglycoside 6\u2032-N-acetyltransferase AAC(6\u2032)-4, fused in vivo with the signal peptide of the Tn3-encoded \u03b2-lactamase","volume":"169","author":"Collatz","year":"1987","journal-title":"J. Bacteriol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.29.5.833","article-title":"Transfer of amikacin resistance by closely related plasmids in members of the family Enterobacteriaceae isolated in Chile","volume":"29","author":"Goldstein","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1128\/jb.170.8.3769-3773.1988","article-title":"Sequencing and expression of the 6\u2032-N-acetyltransferase gene of transposon Tn1331 from Klebsiella pneumoniae","volume":"170","author":"Nobuta","year":"1988","journal-title":"J. Bacteriol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1128\/AAC.46.11.3422-3427.2002","article-title":"Complete nucleotide sequence of Klebsiella pneumoniae multiresistance plasmid pJHCMW1","volume":"46","author":"Sarno","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/nar\/gkt918","article-title":"High-copy bacterial plasmids diffuse in the nucleoid-free space, replicate stochastically and are randomly partitioned at cell division","volume":"42","author":"Tran","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1093\/nar\/gkp208","article-title":"mwr Xer site-specific recombination is hypersensitive to DNA supercoiling","volume":"37","author":"Trigueros","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.03213-14","article-title":"Characterization of Tn6238 with a new allele of aac(6\u2032)-Ib-cr","volume":"59","author":"Quiroga","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/jac\/dkr552","article-title":"A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: Sequence type 512 carrying a plasmid encoding aac(6\u2032)-Ib","volume":"67","author":"Warburg","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e01987-16","DOI":"10.1128\/mBio.01987-16","article-title":"Mechanisms of evolution in high-consequence drug resistance plasmids","volume":"7","author":"He","year":"2016","journal-title":"MBio"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"e00762","DOI":"10.1128\/mBio.00762-15","article-title":"Insertion sequence IS26 reorganizes plasmids in clinically isolated multidrug-resistant bacteria by replicative transposition","volume":"6","author":"He","year":"2015","journal-title":"MBio"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.tim.2014.09.003","article-title":"Carbapenemase-producing Klebsiella pneumoniae: Molecular and genetic decoding","volume":"22","author":"Chen","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/AAC.00452-16","article-title":"Molecular diversity and plasmid analysis of KPC-producing Escherichia coli","volume":"60","author":"Chavda","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.04388-14","article-title":"Complete nucleotide sequence of cfr-carrying IncX4 plasmid pSD11 from Escherichia coli","volume":"59","author":"Sun","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1073\/pnas.1321364111","article-title":"Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae","volume":"111","author":"Deleo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/jac\/dkx131","article-title":"Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles","volume":"72","author":"Chatterjee","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1128\/AAC.00929-10","article-title":"Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: A new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii","volume":"55","author":"Rumbo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1128\/AEM.66.10.4414-4420.2000","article-title":"Vesicle-mediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria","volume":"66","author":"Yaron","year":"2000","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s11658-016-0007-z","article-title":"Natural antisense RNAs as mRNA regulatory elements in bacteria: A review on function and applications","volume":"21","author":"Saberi","year":"2016","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-genet-102209-163523","article-title":"Bacterial antisense RNAs: How many are there, and what are they doing?","volume":"44","author":"Thomason","year":"2010","journal-title":"Annu. Rev. Genet."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1016\/S0021-9258(18)82218-9","article-title":"Mechanisms for negative regulation by iron of the fatA outer membrane protein gene expression in Vibrio anguillarum 775","volume":"268","author":"Waldbeser","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_239","first-page":"3931","article-title":"Plasmid DNA replication","volume":"Volume 6","author":"Flickinger","year":"2010","journal-title":"Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology"},{"key":"ref_240","unstructured":"Tolmasky, M.E., and Alonso, J. (2015). Plasmid Replication Control by Antisense RNAs. Plasmids: Biology and Impact in Biotiechnology and Discovery, ASM Press."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Goyal, N., and Narayanaswami, P. (2017). Making sense of antisense oligonucleotides: A narrative review. Muscle Nerve.","DOI":"10.1002\/mus.26001"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/dkn467","article-title":"Tackling antibiotic resistance: A dose of common antisense?","volume":"63","author":"Woodford","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1475-2859-6-24","article-title":"Hitting bacteria at the heart of the central dogma: Sequence-specific inhibition","volume":"6","author":"Rasmussen","year":"2007","journal-title":"Microb. Cell Fact."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/nyas.12755","article-title":"External guide sequence technology: A path to development of novel antimicrobial therapeutics","volume":"1354","author":"Bonomo","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fgene.2013.00230","article-title":"(Non-)translational medicine: Targeting bacterial RNA","volume":"4","author":"Dinan","year":"2013","journal-title":"Front. Genet."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mib.2016.05.017","article-title":"Antisense antimicrobial therapeutics","volume":"33","author":"Sully","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1128\/AAC.47.10.3296-3304.2003","article-title":"Inhibition of aminoglycoside 6\u2032-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides","volume":"47","author":"Sarno","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.01304-15","article-title":"Inhibition of AAC(6\u2032)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2\u2019,4\u2019-bridged nucleic acid-NC-DNA hybrid oligomer","volume":"59","author":"Lopez","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbt.2010.03.003","article-title":"Inhibition of gene expression by RNase P","volume":"27","author":"Lundblad","year":"2010","journal-title":"New Biotechnol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Jackson, A., Jani, S., Sala, C.D., Soler-Bistue, A.J., Zorreguieta, A., and Tolmasky, M.E. (2016). Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: A methodology for inhibition of expression of antibiotic resistance genes. Biol. Methods Protoc., 1.","DOI":"10.1093\/biomethods\/bpw001"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.01500-06","article-title":"External guide sequences targeting the aac(6\u2032)-Ib mRNA induce inhibition of amikacin resistance","volume":"51","author":"Ha","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"13230","DOI":"10.1073\/pnas.0906529106","article-title":"Inhibition of aac(6\u2032)-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria","volume":"106","author":"Bistue","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_253","first-page":"1","article-title":"Strategies to prolong the useful life of existing antibiotics and help overcoming the antibiotic resistance crisis","volume":"Volume 1","year":"2017","journal-title":"Frontiers in Clinical Drug Research-Anti Infectives"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/cbic.200700677","article-title":"NMR-guided fragment-based approach for the design of AAC(6\u2032)-Ib ligands","volume":"9","author":"Lombes","year":"2008","journal-title":"ChemBioChem"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1039\/C5MD00316D","article-title":"Identification of an inhibitor of the aminoglycoside 6\u2032-N-acetyltransferase type Ib [AAC(6\u2032)-Ib] by glide molecular docking","volume":"7","author":"Chiem","year":"2016","journal-title":"MedChemComm"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1016\/j.bmcl.2013.08.016","article-title":"Inhibitors of the aminoglycoside 6\u2032-N-acetyltransferase type Ib [AAC(6\u2032)-Ib] identified by in silico molecular docking","volume":"23","author":"Lin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cmdc.201100332","article-title":"Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis","volume":"7","author":"Green","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.6b01161","article-title":"Sulfonamide-based Inhibitors of aminoglycoside acetyltransferase Eis abolish resistance to kanamycin in Mycobacterium tuberculosis","volume":"59","author":"Garzan","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1021\/acsinfecdis.6b00193","article-title":"Combating enhanced intracellular survival (Eis)-mediated kanamycin resistance of Mycobacterium tuberculosis by novel pyrrolo[1,5-a]pyrazine-based Eis inhibitors","volume":"3","author":"Garzan","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1021\/acsmedchemlett.6b00261","article-title":"Discovery and optimization of two Eis inhibitor families as kanamycin adjuvants against drug-resistant M. tuberculosis","volume":"7","author":"Garzan","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1128\/AAC.01106-15","article-title":"Inhibition of aminoglycoside 6\u2032-N-acetyltransferase type Ib-mediated amikacin resistance in Klebsiella pneumoniae by zinc and copper pyrithione","volume":"59","author":"Chiem","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1128\/AAC.00885-15","article-title":"Inhibition of aminoglycoside acetyltransferase resistance enzymes by metal salts","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/AAC.00129-14","article-title":"Inhibition of aminoglycoside 6\u2032-N-acetyltransferase type Ib by zinc: Reversal of amikacin resistance in Acinetobacter baumannii and Escherichia coli by a zinc ionophore","volume":"58","author":"Lin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1039\/C4CS00138A","article-title":"Biological metals and metal-targeting compounds in major neurodegenerative diseases","volume":"43","author":"Barnham","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1755-5949.2010.00231.x","article-title":"Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative disorders","volume":"18","author":"Bareggi","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Chiem, K., Hue, F., Magallon, J., and Tolmasky, M.E. (2017). Inhibition of aminoglycoside 6\u2032-N-acetyltransferase type Ib-mediated amikacin resistance by zinc complexed to clioquinol, an ionophore active against tumors and neurodegenerative diseases. Int. J. Antimicrob. Agents.","DOI":"10.1016\/j.ijantimicag.2017.08.002"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Kobayashi, K., Hayashi, I., Kouda, S., Kato, F., Fujiwara, T., Kayama, S., Hirakawa, H., Itaha, H., Ohge, H., and Gotoh, N. (2013). Identification and characterization of a novel aac(6\u2032)-Iag associated with the blaIMP-1-integron in a multidrug-resistant Pseudomonas aeruginosa. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070557"},{"key":"ref_271","unstructured":"Xiong, J., Hawkey, P., and Roy, P.H. (2017, November 11). Novel Class 1 Integrons on Large Plasmids in Multiresistant Pseudomonas aeruginosa Isolated from a Multicenter Survey in Guangzhou, PRC, Available online: https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/208436664."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/AAC.01105-12","article-title":"Novel 6\u2032-N-aminoglycoside acetyltransferase AAC(6\u2032)-Iaj from a clinical isolate of Pseudomonas aeruginosa","volume":"57","author":"Tada","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.03354-14","article-title":"Identification of a novel 6\u2032-N-aminoglycoside acetyltransferase, AAC(6\u2032)-Iak, from a multidrug-resistant clinical isolate of Stenotrophomonas maltophilia","volume":"58","author":"Tada","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/mdr.2015.0126","article-title":"A novel 6\u2032-N-aminoglycoside acetyltransferase, AAC(6\u2032)-Ial, from a clinical isolate of Serratia marcescens","volume":"22","author":"Tada","year":"2016","journal-title":"Microb. Drug Resist."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jac\/dku537","article-title":"New plasmid-mediated aminoglycoside 6\u2032-N-acetyltransferase, AAC(6\u2032)-Ian, and ESBL, TLA-3, from a Serratia marcescens clinical isolate","volume":"70","author":"Jin","year":"2015","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/22\/12\/2267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:54:39Z","timestamp":1760208879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/22\/12\/2267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":275,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["molecules22122267"],"URL":"https:\/\/doi.org\/10.3390\/molecules22122267","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]}}}